Ubiquitin-Proteasome Pathway Assay (CAT#: STEM-MB-0324-WXH)

Ubiquitin-proteasome-mediated protein degradation pathways mainly include:
• The activation of ubiquitin: the carboxyl group of the glycine end of ubiquitin is connected to the sulfhydryl group of ubiquitin activating enzyme E1. This step requires ATP as energy to finally form a thioester bond between ubiquitin and ubiquitin activating enzyme E1.
• E1 delivers the activated ubiquitin to the ubiquitin-conjugating enzyme E2 through the esterification process.
• Ubiquitin ligase E3 connects E2-bound ubiquitin to the target protein and releases E2 to form a specific ubiquitinated protein.
• The ubiquitinated protein is recognized and bound by a specific proteasome, and finally the protein is broken down into short peptides or amino acids under the catalysis of proteases.

To study the regulation mechanism of ubiquitin proteasome signal pathway in disease
To study the effect of each virus on ubiquitin proteasome signaling pathway
To study the effects of drugs or therapies on ubiquitin proteasome signaling pathways

• Luminex Multiplex Assay
• Enzyme-linked immunosorbent assay (ELISA)
• Flow cytometry (FACS analysis) technology

Detectable targets: E1, BID, IAPs, TLR3, SODD, Bad, E2, Bax, PIDD, MYD88, Rac1, TLR4, E3, RIP1, TRAF-2, FADD, APAF-1, BID, FADD, IRF7, Mda-5, NFκB, RIG-1, TRAF3, GAS, IRF9, MEKK1, p38, RIP1, TRAF5, IKK-α, IRS1, MEK6, p50, SLP76, TRAM, IKK-β, IRS2, MSK1, p65, Tak1, TRIF, IPS-1, ISGF3, MSK2, PI3K, TBK1, Vav, IRAK1, ISRE, mTOR, PKR, TLR3